Advertisement


Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

2014 San Antonio Breast Cancer Symposium

Advertisement

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.



Related Videos

Breast Cancer

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.

Breast Cancer

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Lisa A. Carey, MD, on the TNT Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer."

Advertisement

Advertisement



Advertisement